SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its ongoing development, transparency, and dedicated team. Token burns are anticipated as watcher counts increase, and community members are excited about the upcoming airdrop details. The focus remains on long-term growth, with some envisioning Brokecoin as a leading altcoin.

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending amid community discussions around a potential breakout and anticipation for news related to its partnership with Nvidia ($NVDA). Some traders speculate about a possible acquisition, while others are focused on insider trading activity and the impact of the new CEO, Chris Allexandre, on the company's future direction in AI data centers.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amidst mixed community sentiment, with some touting its infrastructure role in Web3 and the potential of its new L1 Neura blockchain for developers, while others express strong dissatisfaction, labeling it a long-term scam and criticizing its price performance compared to other crypto assets. The core debate revolves around the token's utility and the team's ability to deliver tangible value for holders versus its promise as a foundational element for the decentralized web. Discussions also involve broader themes around infrastructure versus hype-driven crypto investments.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as community members highlight its strong ties to the Injective ecosystem and anticipate significant gains. The conversation is driven by Injective's increasing traction and potential ETF, with many believing $NONJA.X offers leveraged exposure to $INJ's growth. Community members emphasize $NONJA.X's unique features, such as its strong community, burned liquidity, and potential for high returns.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to concerns about production timelines for their Gravity SUV and the overall company's profitability, reflected in negative sentiment from some investors. Despite a recent commercial spot during an NFL game and news of accelerated Gravity SUV production, some community members express skepticism about Lucid's financial future and the effectiveness of the reverse stock split. Discussions also involve potential future funding from Saudi PIF and comparisons to other EV manufacturers like Tesla and Rivian.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA.X) is trending amid anticipation for its mainnet launch and excitement surrounding its potential to revolutionize traditional finance. Community members highlight Keeta's anchor technology and partnerships as key drivers for unifying blockchains. The recent listing on exchanges like Coinbase is also fueling positive sentiment, with some suggesting it will replace other blockchains.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending as investors digest mixed signals, including commentary around tariffs and a potential shift towards energy project ownership. Community members are actively debating the impact of government policies and comparing CSIQ's valuation to peers. Bullish sentiment highlights the company's potential in a growing solar market, while bears express concern over debt and profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among healthcare names on Stocktwits.GlucoTrack (GCTK)GlucoTrack posted the highest increase in retail chatter, with message volume surging 3,700% over the past seven days. As of late Sunday, sentiment remained ‘bullish’ among retail traders.On July 8, the company announced the repurchase of over 90% of its Series A Warrants, funded with cash on hand.&nbsp;The move followed last month’s disclosure of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glucotrack-announces-positive-results-from-implantable-blood-glucose-monitor-study/chmJoJwRREo">positive results</a> from its first-in-human clinical study of its continuous blood glucose monitor (CBGM).The implantable device demonstrated 99% data capture, strong accuracy, and no serious adverse events. Designed for a three-year lifespan, the CBGM measures blood glucose directly, not interstitial fluid, and requires no on-body wearable.&nbsp;A long-term feasibility study is expected to launch in Q3 2025.<a href="https://stocktwits.com/symbol/GCTK">GCTK’s stock</a> has declined 98.5% so far in 2025.Sarepta Therapeutics (SRPT)Sarepta saw a 1,991% increase in message volume over the past week, with sentiment remaining ‘extremely bullish’ as of late Sunday, despite mounting regulatory concerns.On July 19, shares plunged over 26% in midday trading after FDA Commissioner Marty Makary said the agency is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-taking-a-hard-look-to-at-whether-sarepta-gene-therapy-elevidys-should-remain-on-the-market/ch8kDByR5qt">“taking a hard look”</a> at whether Sarepta’s gene therapy, Elevidys, should stay on the market.The company disclosed a third patient death on July 18, involving a 51-year-old participant in a limb-girdle muscular dystrophy trial using a similar viral vector to Elevidys. Two earlier deaths were already under FDA investigation. Reuters reported the agency plans to request a voluntary halt to Elevidys' shipments.Amid the fallout,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">analysts criticized Sarepta</a> for not disclosing the fatality earlier, particularly during a recent business update where it announced a 500-job layoff and $400 million in cost cuts.&nbsp;The company has since paused shipments to non-ambulatory patients and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-surges-after-hours-as-it-slashes-500-jobs-amid-fda-black-box-warning-for-gene-therapy-retail-eyes-rebound/ch8KR0HR5oM">agreed to a black box warning</a> for Elevidys, citing the risk of acute liver failure.<a href="https://stocktwits.com/symbol/SRPT">SRPT’s stock</a> has declined 88.7% so far in 2025.TNF Pharmaceuticals (TNFA)TNF Pharma recorded a 1,900% rise in message volume over the past seven days on Stocktwits, with sentiment labeled ‘extremely bullish’ as of late Sunday.Although there was no specific news catalyst driving the buzz last week, the momentum has been strong since last month when TNFA announced a Compassionate Use collaboration with the DADA2 Foundation to study isomyosamine as a treatment for DADA2, a rare pediatric autoinflammatory disorder.In April,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tnf-pharmaceuticals-to-use-ai-to-recruit-patients/chQSz8ARbXp">TNFA partnered with Renova Health</a> to apply AI and machine learning to optimize patient recruitment. The company is analyzing data from 30,000 patients to identify high-risk cohorts, particularly for interventions related to inflammation and side effects of GLP-1 therapy.TNFA’s pipeline includes two drug platforms: isomyosamine, which regulates inflammatory pathways, and Supera-CBD, which targets chronic pain, addiction, and epilepsy.<a href="https://stocktwits.com/symbol/TNFA">TNFA’s stock</a> has declined 92.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-stealthily-hiked-prices-on-everyday-essentials-as-trump-tariffs-bit-report/ch8qvlTR5Ae">Amazon Stealthily Hiked Prices On Everyday Essentials As Trump Tariffs Bit: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GlucoTrack (GCTK), Sarepta Therapeutics (SRPT), and TNF Pharmaceuticals (TNFA) recorded the highest increases in message volume among healthcare names on Stocktwits. (Photo credit: Getty Images)

GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why

GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.

Equity

Shares of TNF Pharmaceuticals, Inc. (TNFA) traded nearly 5% higher on Tuesday afternoon after it announced a partnership with Renova Health for the application of AI and machine learning technologies to recruit patients for its isomyosamine drug development.Isomyosamine is a drug platform based on a clinical stage small molecule that is being developed to treat diseases and disorders marked by acute or chronic inflammation.The clinical-stage pharmaceutical company stated that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.The company stated that the TNF-Renova partnership is analyzing data from 30,000 patients to identify high-risk patients.Renova CEO David Jacobs said that its technology transcends traditional big data analytics by creating highly specific patient personas.“Our platform uncovers the nuanced impact of individual physician practices—such as varying diagnosis codes for GLP-1 prescriptions, like BMI versus diabetes—which can significantly influence cohort selection and study outcomes,” he said.Isomyosamine is the first of two therapeutic platforms being developed by TNF Pharmaceuticals. While Isomyosamine is being developed to regulate inflammation, the company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.On Stocktwits, retail sentiment around TNF remained unmoved in the ‘bearish’ territory over the past 24 hours while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:1292/304;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_22_at_2_09_23_PM_png_87841bd4ef.webp" alt="TNFA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on April 22, 2025 | Source: Stocktwits" width="1292" height="304"><figcaption>TNFA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on April 22, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/TNFA">TNFA stock</a> is down by over 84% so far this year and by over 93% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jd-vance-says-significant-progress-made-with-india-on-trade-deal/chQSwMaRbXn">Vice President JD Vance Calls Indian PM Narendra Modi A ‘Tough Negotiator’ As US, India Negotiate Bilateral Trade Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish

The company said that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment.

The company said that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNF or the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today...

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNFA or the Company), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions...

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNFA or the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and...

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol TNFA Effective Before Market Open Today

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related...

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

TNFA
TNF Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNFA News

TNFA TNF Pharmaceuticals Inc.